Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging
Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging
复制标题
DOI：
10.1093/gerona/gly100
复制
发表时间：
2019-01-01
影响因子：
5.1
通讯作者：
Semba, Richard D.
中科院分区：
文献类型：
--
作者：
Gonzalez-Freire, Marta;Moaddel, Ruin;Semba, Richard D.
步态速度是老年人下肢身体机能的重要衡量标准，可预测残疾和死亡率。下肢身体机能下降的生物学途径尚不清楚。我们使用有针对性的代谢组学方法来识别可预测步态速度随时间变化的血浆代谢物。在巴尔的摩纵向衰老研究 (BLSA) 中，对 504 名 50 岁成年人进行了基线和中位随访 50.5 个月的步态速度测量，这些人在巴尔的摩纵向衰老研究 (BLSA) 中进行了两次或多次研究访问。使用靶向质谱法（AbsoluteIDQ p180 试剂盒，Biocrates）测量血浆代谢物。在测量的 148 种血浆代谢物（氨基酸、生物胺、己糖、甘油磷脂）中，有 8 种与基线时的步态速度显着相关，与年龄和性别无关：己糖（r = 0.148，p < .001）、[鞘磷脂 (SM) 16:1（r = 0.091，p = .0009）、SM 18:0（r = 0.085，p = .002）、SM 18:1（r = 0.128，p < .0001]、磷脂酰胆碱 aa 32:3（r = 0.088，p = .001）、溶血磷脂酰胆碱(LPC) 17:0 (r = 0.083，p = .003)、LPC 18:1 (r = 0.089，p = .001) 和 LPC 18:2 (r = 0.104，p < .0001)。根据基线年龄、性别和慢性疾病进行调整后，基线血浆 LPC 18:2 是步态速度变化率的独立预测因子。在随后的随访中（p = .003），没有其他血浆代谢物与步态速度随时间的纵向变化显着相关。低血浆 LPC 18:2 先前已被证明可以预测糖耐量受损、胰岛素抵抗、2 型糖尿病、冠状动脉疾病和记忆障碍，是老年人步态速度下降的独立预测因子。
Gait speed is an important measure of lower extremity physical performance in older adults and is predictive of disability and mortality. The biological pathways involved in the decline of lower extremity physical performance are not well understood. We used a targeted metabolomics approach to identify plasma metabolites predictive of change in gait speed over time.Gait speed was measured at baseline and over median follow-up of 50.5 months in 504 adults, aged 50 years, who had two or more study visits in the Baltimore Longitudinal Study of Aging (BLSA). Plasma metabolites were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates).Of 148 plasma metabolites (amino acids, biogenic amines, hexoses, glycerophospholipids) measured, eight were significantly associated with gait speed at baseline, independent of age and sex: hexoses (r = 0.148, p < .001), [sphingomyelin (SM) 16:1 (r = 0.091, p = .0009), SM 18:0 (r = 0.085, p = .002), SM 18:1 (r = 0.128, p < .0001], phosphatidylcholine aa 32:3 (r = 0.088, p = .001), lysophosphatidylcholine (LPC) 17:0 (r = 0.083, p = .003), LPC 18:1 (r = 0.089, p = .001), and LPC 18:2 (r = 0.104, p < .0001). Adjusting for baseline age, sex, and chronic diseases, baseline plasma LPC 18:2 was an independent predictor of the rate of change of gait speed over subsequent follow-up (p = .003). No other plasma metabolites were significantly associated longitudinal changes of gait speed over time.Low plasma LPC 18:2, which has previously been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment, is an independent predictor of decline in gait speed in older adults.